Nogreg (Clopidogrel)

Clopidogrel, the active ingredient in Nogreg, is a P2Y12 receptor antagonist presented as a tablet for oral use. It reduces platelet aggregation to prevent thrombotic events in patients with atherosclerotic disease, acute coronary syndrome, recent myocardial infarction, ischemic stroke, and peripheral arterial disease.

GNH USA supplies Nogreg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clopidogrel is an antiplatelet agent used to reduce thrombotic risk in atherosclerotic cardiovascular disease.

- Atherosclerotic disease: prevents thrombotic events in patients with coronary or peripheral artery disease. - Acute coronary syndrome: reduces risk of recurrent ischemic events. - Recent myocardial infarction: lowers incidence of subsequent cardiovascular events. - Ischemic stroke: helps prevent recurrent stroke. - Peripheral arterial disease: decreases risk of limb ischemia.

Clopidogrel may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bleeding gums - Easy bruising - Nausea - Diarrhea - Headache

Serious or Rare Side Effects: - Severe bleeding (intracranial or gastrointestinal) - Thrombotic thrombocytopenic purpura (TTP) - Allergic reactions such as rash or angioedema - Elevated liver enzymes

Before prescribing Clopidogrel, clinicians should consider several safety aspects.

- Assess bleeding risk: evaluate history of hemorrhage before initiating therapy. - Monitor platelet function: periodic labs may be required in high‑risk patients. - Avoid in active pathological bleeding: discontinue if severe bleeding occurs. - Caution with hepatic impairment: dose adjustment may be needed. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Clopidogrel interacts with several drug classes that can alter its efficacy or safety.

Major Interactions (Avoid): - Concurrent use with strong CYP2C19 inhibitors (e.g., omeprazole, fluconazole): may reduce antiplatelet effect. - Combination with other antithrombotic agents (e.g., warfarin, heparin, direct oral anticoagulants): increased bleeding risk. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - CYP2C19 inducers (e.g., rifampin, carbamazepine): may decrease efficacy. - Proton pump inhibitors (e.g., pantoprazole): potential interaction, monitor clinical response. - Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency.